论文部分内容阅读
目的:分析艾滋病患者抗病毒治疗后的临床疗效,比较不同基线CD4+T淋巴细胞计数增长情况。方法:纳入51例符合治疗标准的初治患者,采用国家标准抗病毒治疗一线方案和卫生部统一提供的免费药物,通过对服药后半月、1月、3月、6月、12月的时段进行临床评估和实验室检查,并比较不同基线CD4+T淋巴细胞计数水平治疗后的增长情况。结果:治疗12月后,各方案组疗效无差异,不同基线CD4+T淋巴细胞计数的增长有显著差异。毒副反应为肝损伤、过敏性皮疹,消化道反应为主。结论:HAART可显著的抑制体内HIV病毒的复制,重建机体的免疫功能,缓解患者病情,有利于存活期的延长。严重的毒副作用发生较少。
Objective: To analyze the clinical effect of AIDS patients after antiviral therapy and compare the growth of CD4 + T lymphocyte count at different baseline. Methods: A total of 51 cases of newly diagnosed patients were enrolled in the study. The first-line national standard antiviral therapy and the free drugs provided by the Ministry of Health were included. The half months, January, March, June and December Clinical evaluation and laboratory tests, and compare the growth of different baseline CD4 + T lymphocyte count levels after treatment. Results: After 12 months of treatment, there was no difference in efficacy between different treatment groups. There was a significant difference in the increase of CD4 + T lymphocyte count at different baseline. Toxic side effects of liver injury, allergic rash, mainly gastrointestinal reactions. Conclusion: HAART can significantly inhibit the replication of HIV virus in vivo, rebuild the body’s immune function, relieve the patient’s condition, and prolong the survival period. Serious side effects occur less.